Myomo, Inc. MYO
Industrial Specialties · IPO 2017 · data as of November 13, 2026
Myomo, Inc. (MYO) is a healthcare company listed in the US with a market value of about $49M. In the twelve months to September 30, 2026 it had revenue of $46M and net income of -$15M, a net margin of -33.1%.
Its overall Stock Analiz score is 1.0 out of 5 (weak). The strongest part is future growth (3/5); the weakest is value (0/5).
Key numbers: 5-year revenue growth of 40% a year, a 5-year average ROIC of -58%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 60% below the current price.
About Myomo
Myomo is listed in the US and classified in industrial specialties, IPO year 2017. Revenue went from $1M in 2016 to $41M in 2025, growth of about 49.4% a year. It was profitable in 0 of the last 10 years in our data. Its share count rose by 494% over three years (dilution for shareholders). It spends 17% of revenue on research and development.
Score: 1.0 / 5
Checks passed
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Strong R&D investment or growth above 20%
- 5-year revenue growth above 8% a year
- Stock-based pay below 5% of revenue
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Profit margin improving
- 3-year free cash flow growth above 10% a year
- 5-year EPS growth above 10% a year
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $46M | $41M | $33M | $19M | $16M | $14M | $8M | $4M | $2M | $2M | $1M |
| Net income | -$15M | -$16M | -$6M | -$8M | -$11M | -$10M | -$12M | -$11M | -$10M | -$12M | -$4M |
| Free cash flow | -$7M | -$16M | -$5M | -$6M | -$10M | -$10M | -$9M | -$10M | -$10M | -$6M | -$3M |
| EPS (diluted) | $-0.35 | $-0.37 | $-0.16 | $-0.28 | $-1.52 | $-1.89 | $-3.67 | $-20.79 | $-25.18 | $-87.90 | $-123.90 |
| Net margin | -33.1% | -38.0% | -19.0% | -42.3% | -68.9% | -74.9% | -152.5% | -279.2% | -422.1% | -776.0% | -327.8% |
| ROIC | — | -37.0% | -13.7% | -67.8% | -122.0% | -50.2% | -70.7% | -93.9% | -129.4% | -41.6% | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
Is Myomo stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 60% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Myomo pay a dividend?
Not currently.
Is Myomo a good stock to buy?
We do not give buy or sell advice. Myomo scores 1.0 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.